TY - JOUR
TI - Update on the use of ciclosporin in immune-mediated dermatoses
AU - Griffiths, C. E. M.
AU - Katsambas, A.
AU - Dijkmans, B. A. C.
AU - Finlay,
AU - A. Y.
AU - Ho, V. C.
AU - Johnston, A.
AU - Luger, T. A.
AU - Mrowietz, U.
AU - and Thestrup-Pedersen, K.
JO - British Journal of Dermatology
PY - 2006
VL - 155
TODO - 2
SP - 1-16
PB - Wiley
SN - 0007-0963, 1365-2133
TODO - 10.1111/j.1365-2133.2006.07343.x
TODO - calcineurin inhibitor; ciclosporin; dermatoses; efficacy;
immune-mediated; safety
TODO - Immune-mediated dermatoses, such as psoriasis and atopic dermatitis,
affect a significant proportion of the population. Although most cases
are not life threatening, these diseases can have a profound effect on
the sufferer’s quality of life and that of their family. Systemic
therapy, such as ciclosporin, is often indicated for severe or
recalcitrant disease. The efficacy of ciclosporin in the treatment of
psoriasis and atopic dermatitis has been established and clinical data
also demonstrate its efficacy in treating less common but equally
challenging conditions such as pyoderma gangrenosum, lichen planus,
autoimmune bullous disease, recalcitrant chronic idiopathic urticaria
and chronic dermatitis of the hands and feet. The risk of potential
adverse events associated with ciclosporin is greatly reduced if current
treatment and monitoring guidelines are followed.
ER -